Novo Nordisk A/S NVO New York Stock Exchange

Novo Nordisk A/S (NVO) reported total assets of $542.9B and total liabilities of $348.86B for fiscal year 2025, resulting in total equity of $194.05B.

The company held $26.96B in cash and short-term investments. Total debt stood at $130.96B, with net debt of $104.49B. The Debt-to-Equity (D/E) ratio was 0.67 (moderate).

Current ratio is 0.8, which may signal tight short-term liquidity. Interest coverage is 19.9x (strong).

Criteria supported by this page:

• HEALTH (50/100, Partial) — some metrics are adequate but not all reach ideal thresholds
• MOAT (85/100) — Total assets $542.9B and equity $194.05B support the company's competitive scale
• VALUE (86/100) — Debt-to-Equity 0.67 contributes to the overall valuation risk assessment

Overall SharesGrow Score: 81/100 with 5/7 criteria passed.

AZN

AstraZeneca PLC

$204.38

+1.06%

MRK

Merck & Co., Inc.

$119.96

-0.16%

NVS

Novartis AG

$153.38

-0.71%

TMO

Thermo Fisher Scientific Inc.

$527.22

+2.53%

AMGN

Amgen Inc.

$350.95

+0.32%

ABT

Abbott Laboratories

$101.07

+0.38%

GILD

Gilead Sciences, Inc.

$140.45

+1.02%

PFE

Pfizer Inc.

$27.13

-0.77%